



Academy
Your GMP/GDP
Information Source

SPEAKERS



DOMENICO ANNESE
Johnson & Johnson



ALESSANDRO CASSETTI
Johnson & Johnson



STEVE HAMMOND
Steve Hammond
Consulting



DR MARTIN MAUS
Boehringer Ingelheim
Pharma



RICHARD STEINER
GEA



ANTHONY TANTUCCIO
Merck & Co, US



FRANK WITULSKI
Merck & Co, US



JAN VERELST
Siemens



Image: GEA

LIVE ONLINE CONFERENCE | 19/20 OCTOBER 2021

CONTINUOUS MANUFACTURING FROM DEVELOPMENT TO OPERATION

HOW TO DEVELOP, IMPLEMENT AND OPERATE
CONTINUOUS OSD MANUFACTURING

HIGHLIGHTS:

- The actual Continuous Manufacturing Landscape
- Technology for Continuous Manufacturing
 - Wet & Dry Granulation
 - Direct compression
- Development of a Continuous Manufacturing Process
 - Prerequisites
 - Usage of DoE
 - How to determine the ResidenceTimeDistribution?
- Set-up of a Control Strategy
- Measurement & Control
 - Usage of PAT
 - Data Management
 - Sensor Interfaces
- Operation of a Continuous Process
 - Handling of non-conforming Material
 - Cleaning
- How to implement Real Time Release?
- Case Studies from MSD and J&J



This conference is recognised for the ECA GMP Certification Programme „Certified Technical Operations Manager“. Please find details at www.gmp-certification.eu

CONTINUOUS MANUFACTURING FROM DEVELOPMENT TO OPERATION

LIVE ONLINE CONFERENCE | 19/20 OCTOBER 2021

Objectives It is the aim of this event to show how a continuous manufacturing process for oral solid dosage forms can be developed and set into operation. Questions regarding materials, technology, process controls and GMP/Quality Assurance will be discussed and answered.

Background Solid dosage forms are still the most common dosage form, first and foremost tablets without any pioneering developments in the recent years. But driven by only a few pharmaceutical companies more and more of the global players started to invest in continuous manufacturing (CM). Companies like Johnson & Johnson, Vertex, Pfizer and Merck work intensively on the development of continuous processes with some products already approved. This change from batch-to-batch to the continuous mode of operation is one of the largest paradigm changes in the pharmaceutical industry ever.

Continuous manufacturing is data driven and by gaining this flood of information two topics become very important: process control and process monitoring. The residence time of the materials processed becomes another important quality aspect. Time now also is the most important parameter for scale-up, not the volume of the equipment any more.

So a large amount of data has to be evaluated in order to control the process and to decide whether material can be collected or has to be rejected. This fundamental shift is also a major challenge for the Quality Unit. The Quality Management System has to be adapted to also cover continuous processes.

Regulating authorities, first of all the FDA, also encourage the transition from batch to continuous production. They expect an increase in product safety while equipment suppliers promote a decrease of production costs. Pharmaceutical companies emphasize the savings of time and materials needed during the development and transfer phases.

But with a continuous mode of operation new questions rise:

- How should a batch be defined? Is there a difference between lot and batch?
- What are the prerequisites for the development of a continuous process?
- What new risks does a continuous process involve?
- How can a continuous manufacturing line look like?
- How can a continuous process be kept in a controlled state?
- How is a continuous process validated?
- How to determine the ResidenceTimeDistribution – what about material traceability?
- How should deviations in a continuous process be handled?
- How should equipment cleaning and maintenance be scheduled?
- Which documents do the authorities require for approval of continuous processes?

Listen to companies who already did the transition and learn how they answered the questions above.

Target Audience This conference addresses specialists and executives working in the fields of pharmaceutical development, manufacture and quality assurance as well as technicians, planners and plant designers, especially those involved in the set up of continuous lines for manufacture of oral solid dosage forms.

Programme **The recent Continuous Manufacturing Landscape**

- Introduction to Continuous Manufacturing
- From Early ideas to current solutions
- Reasons to go Conti
- A brief market overview- unit operations, suppliers & users...
- Different approaches to CM
 - Direct Compression
 - Roller Compaction &Tableting
 - TSG/Fluidbed Granulation & Tableting

Programme

Prerequisites: how to start with Continuous Manufacturing

- Is a new product suitable for CM?
- What are the business drivers for this product and how can CM meet those goals?
- Evaluation of material properties for CM (e.g. flow, feeding variability, etc.)
- Process modelling
- Control strategy considerations

Using DoE for the development of continuous processes

- Basis of using DoE in process development
- How to start
- Data evaluation
- Limitations
- Example: continuous twin screw granulation (TSG)

Measurement points and sensor interfaces

- Sampling
- PAT techniques
- Mass balance models

Integrated PAT data management on continuous pharmaceutical lines

- Integration of (different) PAT tools into an (existing) automation environment
- Structured data management of data from different data sources
- Real-time monitoring of CQA's
- Product diverting & Advanced Process Control
- Some use cases

Development of a control strategy

- Different approaches
- RTD and its determination
- Material traceability
- Risk analyses

Real time release

- What does this mean?
- Benefits?
- Registered Examples

J&J experience: CM from equipment qualification to regulatory submission

- Overview of the three technologies used at J&J Pharma
 - Wet granulation
 - Dry granulation
 - Direct compression
- SDNV approach for qualification
- Control strategy – practical aspects
 - PAT integration
 - CPPs monitoring
 - RTD
 - Rejection strategy
- Cleaning & Change Over challenge
- Experiences from Regulatory submission

Case Study Merck US: Continuous Manufacturing using Direct Compression

- Experiences with developing, commercializing, and filing Merck's first CM product.
- Use of an RTD Process Model for Rejection in a CDC process.
- Look-ahead towards future innovations with Continuous Manufacturing

SPEAKERS



DOMENICO ANNESE | Johnson & Johnson | Technical Operation Sr. Lead

Domenico has 10 years of experience in J&J in different roles, for example in Quality, Execution Systems, Operations (formulation) and lastly as Technical Operations Sr Lead, responsible for the introduction of new products and Technical Transfers for batch mode and continuous manufacturing mode.



ALESSANDRO CASSETTI | Johnson & Johnson | Operation Manager

Alessandro has 9 years of experience in J&J covering different responsibilities in QC and Technical Operations as scientist on continuous manufacturing as well as Operation Manager responsible for new products (batch and CM mode).



STEVE HAMMOND | Steve Hammond Consulting | Owner

Steve Hammond has more than 30 years of experience in developing and deploying PAT in the Pharmaceutical Industry. He has been working for Pfizer as Director of the Process Analytical Support Group and led the efforts to develop and deploy PAT within Pfizer Pharmaceuticals Manufacturing division. Now he runs his own consultancy business with focus on Process Analytical Sciences.



DR MARTIN MAUS | Boehringer Ingelheim Pharma | Principal Scientist

Martin is a Principal Scientist at Boehringer Ingelheim in Biberach where is working in late stage product development of solid oral dosage forms.



RICHARD STEINER | GEA | Global Sales Director for Continuous Processing Technologies

Richard Steiner is a mechanical engineer and worked in different management positions during his times at Leistritz. In 2012 he joined GEA and is today Global Sales Director for Continuous Processing Technologies at GEA Pharma Systems.



ANTHONY TANTUCCIO | Merck & Co, US | Senior Scientist

Anthony Tantuccio is a Senior Scientist in the Pharmaceutical Commercialization Technology group at Merck & Co. in the US. He leads the technology development team with the mission to build out processes for the successful adoption of continuous manufacturing. He is the lead designer of Merck's pilot non GMP and clinical GMP continuous manufacturing lines.



FRANK WITULSKI | Merck & Co, US | Director of Engineering

Frank Witulski is a Director of Engineering in Merck's Pharmaceutical Commercialization Technology department and holds a Master of Science in Chemical Engineering. He has over 19 years of experience in process and packaging development and commercialization of OSD products, and has spent the last 4 years leading the group responsible for commercializing Merck's first continuous direct compression process.



JAN VERELST | Siemens | Global Business Development Manager for SIPAT

Jan Verelst is a chemical Engineer with 27 year of experience with CDS, LIMS and PAT Systems. Currently Jan holds the position of Global Business Development Manager for SIPAT, the PAT data management solution of Siemens, focusing on Pharmaceutical Industries.

Your Benefits

Internationally Acknowledged Certificate from ECA Academy

The EU GMP Guide requires: „... All personnel should be aware of the principles of Good Manufacturing Practice that affect them and receive initial and continuing training,...“. This is why you receive an acknowledged participant certificate, which lists the contents of the seminar in detail and with which you document your training.



This could be of interest for you as well

Would you like to train a larger group of participants in your company?

We offer practice-oriented GMP/GDP training courses on:

- Basic GMP
- APIs (ICH Q7)
- Medicinal Products
- Biopharmaceuticals
- Quality Assurance
- Quality Control
- Validation/Qualification
- Regulatory Affairs
- Sterile Manufacturing
- IT / Computer Validation
- Good Distribution Practice (GDP)
- Data Integrity
- Packaging
- Medical Devices
- Technical Operations

You will find a time schedule for each training course at www.gmp-compliance.org/training/gmp-gdp-in-house-trainings

Why not online? GMP/GDP Training Courses/ Conferences, Webinars and E-Learning

Take advantage of the wide range of "on demand" training opportunities offered by the ECA Academy. You can use various online offers at any time without software installation. There is an extensive selection of courses available. Simply book online - with a certificate of completion, of course. Find out more at www.gmp-elearning.com and www.gmp-compliance.org/gmp-webinars/recorded-gmp-webinars.

Easy Registration



Reservation Form:
CONCEPT HEIDELBERG
P.O. Box 10 17 64
69007 Heidelberg
Germany



Reservation Form:
+ 49 6221 84 44 34



e-mail:
info@concept-heidelberg.de



Internet:
www.gmp-compliance.org



Date of Live Online Conference

Tuesday, 19 October 2021;
09.00 to approx. 17.15 h
Wednesday, 20 October 2021,
09.00 to approx. 16.30 h

All times mentioned are CEST.

Technical Requirements

For our Live Online Training Courses and Webinars, we use Cisco WebEx, one of the leading suppliers of online meetings. At <http://www.webex.com/test-meeting.html> you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and e-mail address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

Fees (per delegate plus VAT)

ECA Members EUR 1,490.-
APIC Members EUR 1,590.-
Non-ECA Members EUR 1,690.-
EU GMP Inspectorates EUR 845.-
The conference fee is payable in advance after receipt of invoice.

Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

Presentations/Certificate

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

Conference language

The official conference language will be English.

Ordering Recordings

Independent from the Live Online Training Courses, you can also order recordings of selected Live Online Training Courses at the same conditions – at www.gmp-compliance.org/recordings. These recordings will be provided on our media server. All you need to watch it is an Internet browser – no additional software.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.

CONCEPT HEIDELBERG
P.O. Box 10 17 64
D-69007 Heidelberg, Germany
Phone +49 (0) 62 21/84 44-0
Fax +49 (0) 62 21/84 44 34
info@concept-heidelberg.de
www.concept-heidelberg.de

For questions regarding content please contact:

Dr Robert Eicher (Operations Director)
at +49-62 21/84 44 12, or per e-mail at eicher@concept-heidelberg.de.

For questions regarding organisation please contact:

Niklaus Thiel (Organisation Manager) at
+49-62 21/84 44 43, or per e-mail at thiel@concept-heidelberg.de.

If the bill-to-address deviates from the specification to the right, please fill out here:

Reservation Form (Please complete in full)

+49 6221 84 44 34



CONTINUOUS MANUFACTURING FROM DEVELOPMENT TO OPERATION
LIVE ONLINE CONFERENCE | 19/20 OCTOBER 2021

Mr Ms

Title, first name, surname

Company

Department

Important: Please indicate your company's VAT ID Number

Purchase Order Number, if applicable

Street / P.O. Box

City

Zip Code

Country

Phone / Fax

E-Mail (Please fill in)

General terms and conditions

If you cannot attend the conference you have two options:
1. We are happy to welcome a substitute colleague at any time.

2. If you have to cancel entirely we must charge the following processing fees: Cancellation

- until 2 weeks prior to the conference 10 %
- until 1 weeks prior to the conference 50 %
- within 1 week prior to the conference 100 %.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event.

If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part, you have to inform us in writing.

The cancellation fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)! (As of January 2012).

German law shall apply. Court of jurisdiction is Heidelberg.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept

Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.